Ochre Bio: Raises $9.6M in Seed Financing

Ochre Bio: Raises $9.6M in Seed Financing

  • Ochre Bio, an Oxford, England, UK-based biotech company developing RNA medicines for chronic liver diseases, closed a $9.6M seed financing
  • The round was led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek
  • The company intends to use the funds to advance the development of its RNA therapies and expand their deep phenotyping platform to identify and validate new liver targets
  • The company is a biotechnology company developing RNA medicines for chronic liver diseases
  • The company has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines
  • In addition to deep phenotyping of human livers, the company is able to test therapeutics in explanted livers being maintained extracorporeally
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Salmon Strengthens Fundraising for Philippines Expansion

Fintech company Salmon secures new funding to enhance its operations in the Philippines.Highlights: Salmon raises significant funds to...

Truist Pilots Zelle Bill Payments, Strengthening Digital Banking Services

New pilot program aims to simplify bill payments through Zelle for customers.Highlights: Truist launches pilot program for Zelle...

ACI Worldwide Strengthens Payment Solutions with Cloud-Native Platform

New platform enhances support for eight U.S. payment networks.Highlights: ACI Worldwide launches a cloud-native payment platform.The platform supports...

LendingClub Rebrands as Happen Bank, Strengthens Digital Banking Services

The transformation aims to enhance customer engagement and streamline services.Highlights: LendingClub officially rebrands to Happen Bank.The rebrand focuses...